

Antonio Perez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/252479/publications.pdf>

Version: 2024-02-01

62
papers

1,331
citations

430874

18
h-index

377865

34
g-index

70
all docs

70
docs citations

70
times ranked

2037
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucocorticoid-induced hyperglycemia (ç³–çš@è“æž€çê±â¼çš„é«~è¡€ç³–). Journal of Diabetes, 2014, 6, 9-20.	1.8	176
2	Unchanged Hypovitaminosis D and Secondary Hyperparathyroidism in Morbid Obesity after Bariatric Surgery. Obesity Surgery, 2005, 15, 330-335.	2.1	140
3	Prevalence and Phenotypic Distribution of Dyslipidemia in Type 1 Diabetes Mellitus. Archives of Internal Medicine, 2000, 160, 2756.	3.8	63
4	A Randomized Controlled Trial of Continuous Positive Airway Pressure on Glucose Tolerance in Obese Patients with Obstructive Sleep Apnea. Sleep, 2016, 39, 35-41.	1.1	60
5	Non-HDL Cholesterol and Apolipoprotein B in the Dyslipidemic Classification of Type 2 Diabetic Patients. Diabetes Care, 2003, 26, 2048-2051.	8.6	54
6	Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. Cardiovascular Diabetology, 2013, 12, 112.	6.8	47
7	Fat Distribution and Metabolic Abnormalities in HIV-Infected Patients on First Combination Antiretroviral Therapy Including Stavudine or Zidovudine: Role of Physical Activity as a Protective Factor. Antiviral Therapy, 2003, 8, 223-231.	1.0	43
8	Effect of Improving Glycemic Control in Patients With Type 2 Diabetes Mellitus on Low-Density Lipoprotein Size, Electronegative Low-Density Lipoprotein and Lipoprotein-Associated Phospholipase A2 Distribution. American Journal of Cardiology, 2012, 110, 67-71.	1.6	37
9	Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis. Atherosclerosis, 2016, 247, 161-169.	0.8	34
10	The Association of Hypovitaminosis D with the Metabolic Syndrome Is Independent of the Degree of Obesity. Isrn Endocrinology, 2012, 2012, 1-5.	2.0	33
11	Lipidomic changes of LDL in overweight and moderately hypercholesterolemic subjects taking phytosterol- and omega-3-supplemented milk. Journal of Lipid Research, 2015, 56, 1043-1056.	4.2	32
12	Phytosterols and Omega 3 Supplementation Exert Novel Regulatory Effects on Metabolic and Inflammatory Pathways: A Proteomic Study. Nutrients, 2017, 9, 599.	4.1	27
13	Insulin Therapy in Hospitalized Patients. American Journal of Therapeutics, 2020, 27, e71-e78.	0.9	27
14	Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes. Cardiovascular Diabetology, 2018, 17, 156.	6.8	26
15	Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8Âmg Liraglutide Versus Sitagliptin. Diabetes Therapy, 2015, 6, 61-74.	2.5	24
16	Epidemiology, Quality of Life, and Costs Associated with Hypoglycemia in Patients with Diabetes in Spain: A Systematic Literature Review. Diabetes Therapy, 2019, 10, 375-392.	2.5	21
17	Cardiovascular Disease in Type 1 Diabetes Mellitus: Epidemiology and Management of Cardiovascular Risk. Journal of Clinical Medicine, 2021, 10, 1798.	2.4	21
18	A rare STAP1 mutation incompletely associated with familial hypercholesterolemia. Clinica Chimica Acta, 2018, 487, 270-274.	1.1	19

#	ARTICLE	IF	CITATIONS
19	Maturity-onset diabetes of the young: From a molecular basis perspective toward the clinical phenotype and proper management. <i>Endocrinología, Diabetes Y Nutrición</i> , 2020, 67, 137-147.	0.3	19
20	Hypovitaminosis D in type 2 diabetes: relation with features of the metabolic syndrome and glycemic control. <i>Endocrine Research</i> , 2015, 40, 160-165.	1.2	18
21	Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 6.	2.7	18
22	Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6273.	4.1	18
23	Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113â€“122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice. <i>Biomolecules</i> , 2020, 10, 829.	4.0	18
24	Modified low-density lipoproteins as biomarkers in diabetes and metabolic syndrome. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 1220-1240.	3.0	17
25	Inpatient Hyperglycemia Management and COVID-19. <i>Diabetes Therapy</i> , 2021, 12, 121-132.	2.5	17
26	Increased concentration of clusterin/apolipoprotein J (apoJ) in hyperlipemic serum is paradoxically associated with decreased apoJ content in lipoproteins. <i>Atherosclerosis</i> , 2015, 241, 463-470.	0.8	15
27	Lipoproteínas modificadas como marcadores de riesgo cardiovascular en la diabetes mellitus. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2013, 60, 518-528.	0.8	14
28	Increased inflammatory effect of electronegative LDL and decreased protection by HDL in type 2 diabetic patients. <i>Atherosclerosis</i> , 2017, 265, 292-298.	0.8	14
29	Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1452-1462.	1.5	14
30	Statin-related myotoxicity. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2016, 63, 239-249.	0.8	13
31	COVID-19 and Diabetes. <i>Journal of Clinical Medicine</i> , 2021, 10, 5341.	2.4	13
32	Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 7.	2.7	12
33	A randomized controlled trial: branchedâ€“chain amino acid levels and glucose metabolism in patients with obesity and sleep apnea. <i>Journal of Sleep Research</i> , 2017, 26, 773-781.	3.2	12
34	Soluble LRP1 is an independent biomarker of epicardial fat volume in patients with type 1 diabetes mellitus. <i>Scientific Reports</i> , 2018, 8, 1054.	3.3	11
35	Consecuencias de la COVID-19 sobre las personas con diabetes. <i>Endocrinología, Diabetes Y Nutrición</i> , 2020, 67, 355-356.	0.3	11
36	Effects of Bariatric Surgery on HDL Cholesterol. <i>Obesity Surgery</i> , 2020, 30, 1793-1798.	2.1	11

#	ARTICLE	IF	CITATIONS
37	Transition from intravenous insulin to subcutaneous long-acting insulin in critical care patients on enteral or parenteral nutrition. <i>Endocrinologia, Diabetes Y Nutrici3n</i> , 2017, 64, 552-556.	0.3	10
38	Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001518.	2.8	10
39	Molecular mapping of platelet hyperreactivity in diabetes: the stress proteins complex HSPA8/Hsp90/CSK21± and platelet aggregation in diabetic and normal platelets. <i>Translational Research</i> , 2021, 235, 1-14.	5.0	10
40	Eficacia y seguridad de empagliflozina en combinaci3n con otros hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2016, 63, 519-526.	0.8	9
41	Changes in the Composition and Function of Lipoproteins after Bariatric Surgery in Patients with Severe Obesity. <i>Journal of Clinical Medicine</i> , 2021, 10, 1716.	2.4	8
42	Standardization of a method to evaluate the antioxidant capacity of high-density lipoproteins. <i>International Journal of Biomedical Science</i> , 2009, 5, 402-10.	0.1	8
43	Modified lipoproteins as biomarkers of cardiovascular risk in diabetes mellitus. <i>Endocrinolog3a Y Nutrici3n (English Edition)</i> , 2013, 60, 518-528.	0.5	7
44	Consequences of COVID-19 on people with diabetes. <i>Endocrinolog3a Diabetes Y Nutrici3n (English Ed)</i> , 2020, 67, 355-356.	0.2	7
45	Eficacia de un programa de tratamiento de la hiperglucemia en un Servicio de Cirug3a Vascular supervisado por Endocrinolog3a. <i>Cirug3a Espa3ola</i> , 2016, 94, 392-398.	0.2	6
46	Differences in Glycemic Control in Diabetic and Non-diabetic Patients with Parenteral Nutrition Using a Basal plus Correction Insulin Regimen: An Observational, Retrospective Study. <i>Diabetes Therapy</i> , 2018, 9, 1359-1367.	2.5	6
47	Is Sleeve Gastrectomy as Effective in Older Patients as in Younger Patients? A Comparative Analysis of Weight Loss, Related Comorbidities, and Medication Requirements. <i>Obesity Surgery</i> , 2022, 32, 1909.	2.1	6
48	Familial Combined Hyperlipidemia (FCH) Patients with High Triglyceride Levels Present with Worse Lipoprotein Function Than FCH Patients with Isolated Hypercholesterolemia. <i>Biomedicines</i> , 2020, 8, 6.	3.2	5
49	The association between hypovitaminosis D and metabolic syndrome: current understanding. <i>Clinical Lipidology</i> , 2015, 10, 513-524.	0.4	4
50	Statin-related myotoxicity. <i>Endocrinolog3a Y Nutrici3n (English Edition)</i> , 2016, 63, 239-249.	0.5	4
51	Effectiveness of Bariatric Surgery in Patients with the Metabolically Healthy Obese Phenotype. <i>Obesity Surgery</i> , 2021, 31, 517-522.	2.1	4
52	Cost Analysis of FreeStyle Libre2 System in Type2 Diabetes Mellitus Population. <i>Diabetes Therapy</i> , 2021, 12, 2329-2342.	2.5	4
53	Implantaci3n de un programa para el manejo de la hiperglucemia en la hospitalizaci3n con la incorporaci3n de la enfermera consultora. <i>Endocrinologia, Diabetes Y Nutrici3n</i> , 2020, 67, 461-468.	0.3	3
54	Diabetes Does Not Increase the Risk of Hospitalization Due to COVID-19 in Patients Aged 50 Years or Older in Primary Care"APHOSDIAB" COVID-19 Multicenter Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2092.	2.4	3

#	ARTICLE	IF	CITATIONS
55	Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease. <i>Endocrinología Y Nutrición</i> (English Edition), 2011, 58, 283-290.	0.5	2
56	Glycemic control at hospital: Why does it not improve?. <i>Endocrinología Y Nutrición</i> (English Edition), 2012, 59, 153-154.	0.5	2
57	Statin-centered treatment of dyslipidemia. New evidence-based paradigm, or only part of the evidence?. <i>Endocrinología Y Nutrición</i> (English Edition), 2016, 63, 1-3.	0.5	2
58	Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program. <i>Diabetes Therapy</i> , 2019, 10, 1893-1907.	2.5	2
59	Association of the KDIGO Risk Classification with the Prevalence of Heart Failure in Patients with Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2021, 10, 4634.	2.4	2
60	Tratamiento estatino-céntrico de la dislipemia. ¿Nuevo paradigma basado en la evidencia o solo parte de la evidencia?. <i>Endocrinología Y Nutrición: Órgano De La Sociedad Española De Endocrinología Y Nutrición</i> , 2016, 63, 1-3.	0.8	1
61	¿PUEDE LA PANDEMIA DE COVID-19 SER UNA OPORTUNIDAD DE MEJORA PARA NUESTRA ACTIVIDAD ASISTENCIAL, FORMATIVA Y DE INVESTIGACIÓN?. <i>Endocrinología Y Nutrición</i> (English Ed), 2021, 68, 79-81.	0.2	0
62	Executive summary on the treatment of type 2 diabetes mellitus in elderly or frail individuals. 2022 update of the 2018 consensus document "Treatment of type 2 diabetes mellitus in the elderly". <i>Revista Clínica Española</i> , 2022, , .	0.5	0